Vistagen Therapeutics (NASDAQ:VTGN) Stock Passes Above 50 Day Moving Average – What’s Next?

Vistagen Therapeutics, Inc. (NASDAQ:VTGN)’s share price passed above its 50 day moving average during trading on Thursday . The stock has a 50 day moving average of $2.84 and traded as high as $2.90. Vistagen Therapeutics shares last traded at $2.87, with a volume of 182,113 shares traded.

Vistagen Therapeutics Stock Performance

The company has a market capitalization of $84.56 million, a PE ratio of -1.98 and a beta of 0.77. The company’s 50-day moving average is $2.85 and its 200 day moving average is $2.98.

Vistagen Therapeutics (NASDAQ:VTGN) last announced its quarterly earnings results on Thursday, February 13th. The company reported ($0.46) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.48) by $0.02. The firm had revenue of $230 billion for the quarter, compared to the consensus estimate of $0.18 million. Vistagen Therapeutics had a negative return on equity of 48.12% and a negative net margin of 6,777.08%. On average, analysts forecast that Vistagen Therapeutics, Inc. will post -1.77 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. HighTower Advisors LLC purchased a new position in Vistagen Therapeutics in the third quarter worth about $64,000. Jane Street Group LLC bought a new position in shares of Vistagen Therapeutics in the third quarter worth approximately $59,000. Valence8 US LP purchased a new stake in shares of Vistagen Therapeutics in the third quarter worth $103,000. Virtu Financial LLC raised its position in shares of Vistagen Therapeutics by 30.5% during the 3rd quarter. Virtu Financial LLC now owns 20,210 shares of the company’s stock valued at $61,000 after purchasing an additional 4,722 shares during the period. Finally, Boothbay Fund Management LLC bought a new stake in shares of Vistagen Therapeutics during the 4th quarter valued at $66,000. Institutional investors own 78.39% of the company’s stock.

About Vistagen Therapeutics

Vistagen Therapeutics, Inc, a late clinical-stage biopharmaceutical company, primarily focus to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders. The company's pipeline includes six clinical stage product candidates, including five investigational agents belonging to drugs known as pherines.